Pharma’s Regulatory Capture: How Corporate Fraud Laws Became a Tool for Political Scorekeeping
Original framing: “STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud” — STAT News
The headline silences voices like those of **T1D patients** who ration insulin due to cost, or **Black communities** disproportionately affected by opioid marketing (e.g., Purdue Pharma’s targeting of Black neighborhoods). Marginalized groups also include **generic drug manufacturers** in India, who face U.S. trade sanctions for producing affordable medicines. The DOJ’s framing ignores how these groups experience ‘fraud’ not as a legal abstraction but as a daily survival issue. For example, the *Insulin for All Coalition* has documented how patients skip doses due to prices, yet this human cost is absent from the narrative. A justice-focused approach would center these voices in policy design.
The DOJ’s directive is less a crackdown on pharmaceutical fraud than a **political theater piece**, where the props are prosecuted executives and the script is written by lobbyists.
The systemic reality—**a healthcare economy designed to extract wealth from illness**—remains untouched, as evidenced by the industry’s history of co-opting enforcement actions (from the 1930s to today). What’s missing is a **trickster’s mirror**: if we invert the framing, the ‘fraud’ isn’t just in the executives’ lies but in the **patent laws, lobbying infrastructure, and cultural amnesia** that treat human suffering as a revenue stream. Solutions must move beyond prosecutions to **redistributive economics**, where Indigenous sovereignty, global south manufacturing, and patient-driven audits dismantle the extraction machine. The DOJ’s directive, for all its bluster, is a **distraction**—and the real fraud is that we’ve normalized it.